SciSparc: Subsidiary NeuroThera Labs’ CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company’s Quantum Architecture
Key Highlights
- ➤CliniQuantum achieved approximately 16.8-fold acceleration with one NVIDIA T4 GPU
- ➤Algorithm analyzed 7,331,162,245 three-gene combinations from 3,531 genes
- ➤Analysis identified approximately 22.2 million correlated gene triplets
- ➤GPU processing took approximately 0.5 hours versus 8.4 hours using 64 vCPUs
- ➤Benchmark did not establish clinical validity, predictive value, or utility of gene combinations
TEL AVIV, Israel, Oct. 07, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, that CliniQuantum Ltd. (“CliniQuantum”), NeuroThera’s majority owned subsidiary, reported that its Graphics Processing Unit- accelerated (“GPU”) quantum-simulation platform achieved an approximately 16.8-fold computational acceleration using a single machine with 64 cores (x86_64) and a single NVIDIA T4 Tensor Core GPU compared with the same 64-vCPU machine with only Central Processing Unit (“CPU”) implementation.
The evaluation used a real clinical gene-expression dataset comprising 11 patients and 3,531 gene-expression features, representing a challenging high-dimensional setting in which the number of biological variables greatly exceeds the number of patients.
Get started
Create a free account to read the full story.